Venetoclax is a selective B-cell lymphoma-2(Bcl-2)inhibitor,widely used in the treatment of hematologic malignancies with good efficacy.Its primary adverse effects include cytopenias,infections,gastrointestinal reactions,and electrolyte disturbances,with the potential for severe tumor lysis syndrome in chronic lymphocytic leukemia.The patient,a 75-year-old male,was admitted to Baoding No.1 Hospital on January 6,2023,with a diagnosis of refractory relapsed Ph-like acute lymphoblastic leukemia.Tumor lysis syndrome with acute renal failure,hyperkalemia,hypocalcemia,oliguria,hyperuricemia,and rapid onset of severe cytopenia and neutropenia occurred 3.5 hours after administering 100 mg of venetoclax.Despite symptomatic and supportive treatment leading to the recovery of renal function,the patient continued to experience persistent pancytopenia with severe infections and ultimately died.
国家科技期刊平台
NSTL
万方数据
